Noobie123 I also hope Sinopharm get approved by NPRA
----------------
Betul. Saya pun dalam situasi sama. Hanya harapan saja yang dapat dikongsi.

Untuk saya, saya terlekat dalam satu saham saya cuba ambil langkah yang saya kira positif untuk membantu kaunter tersebut supaya ada harapan untuk naik kembali. Hanya usaha, kejayaan ditentukan oleh minat pelabur-pelabur di pasaran dan juga operator, kalau ada.

Berbeza, ada sesetengah orang yang lain, bila terlekat sesuatu kaunter saham, frust dan ambil jalan kutuk kaunter tersebut. Mungkin cara tersebut juga sesuai dengan matlamat mereka, termasuk untuk turunkan harga bagi beli balik pada harga rendah untuk average down saham mereka.

Noobie123 Bingo....If Sinopharm was truly just registered with NPRA.
The big question is "IF" which means don't know, unsure, not confirmed.
----------------
Betul tu. Saya bukan insider atau agen kepada insider pun. Semua berdasarkan cerita / report yang diperoleh dari web.

Awak tengok, saya berhati-hati dalam laporan saya. Seboleh-bolehnya laporkan berita berdasarkan report sebenar.

Tak ada siapa pun saya point senapang untuk tembak untuk membaca dan percaya idea ini. Tapi adat nak share, itu saja.

Apa-apa keputusan ambil keputusan sendiri. TAYOR

@18KHarmoni.

Itu saja kah yang awak boleh cakap. Kalau nak kaunter atau menidakkan pandangan saya pun jadilah sedikit rasinal dengan pandangan bernas dan bukti yang awak boleh kemukakan.

Saya tak suka cakap kosong seperti setengah orang. Ada bukti dan pakai logik.

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO).
--------------------
I want to stress on this.

If the Sinopharm was truly just registered with NPRA, the process of approval should be more shorter in time compared with the vaccine candidate which not been approved by WHO yet.

Note: Sinopharm vaccine has been approved by WHO.

On the Sputnik Covid-19 vaccine produced by Russia, Khairy said that Duopharma Biotech Bhd’s wholly-owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), which holds the distribution rights to the product, has three months to register the vaccine with the National Pharmaceutical Regulatory Agency (NPRA), after inking an agreement with the government earlier this month.

He said that the NPRA still requires further information on the vaccine.

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO). Sputnik has not received the EUL from WHO yet,” he said, referring to the Emergency Use Listing.

Source: https://www.malaymail.com/news/malaysia/2021/06/21/khairy-cansino-vaccine-to-arrive-in-malaysia-next-month-no-updates-yet-on-j/1983852

An update on the prospect of Kanger to be involved as the distributor of Sinopharm Covid-19 vaccine in Malaysia:

Report 1: 9 March 2021.

Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.

In a bourse filing today, the group said the 10,000 doses of the vaccine will be for trial purposes and that it will be getting the necessary approvals from the relevant authorities.

“The first batch of vaccines is expected to arrive in May 2021,” Kanger stated.
Sinopharm has Covid-19 vaccine candidates that are undergoing stage 3 clinical trials

Source: https://www.theedgemarkets.com/article/kanger-receive-10000-doses-sinopharm-covid19-vaccine%C2%A0-may-trial-purposes

Report 2: 21 May2021.

The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA), says Khairy Jamaluddin (pic).

The National Covid-19 Immunisation Programme coordinating minister said that this DID NOT HAVE TO GO THROUGH PHARMANIAGA, the local registration product holder for the Sinovac vaccine.

He said there were several parties interested in bringing the Sinopharm vaccine from China.

“It can go through anybody else who wants to try and bring in the vaccine. It can be registered with the NPRA,” he said in a video late Thursday (May 20) to address several allegations made by Opposition leader Datuk Seri Anwar Ibrahim about the immunisation programme.
Source: https://mywinet.com/covid-19-those-who-want-to-bring-in-sinopharm-vaccine-can-register-it-with-npra-says-khairy/

Report 3: 27 May2021.
“the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.”
Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/

MY FINDINGS:
1. Kanger planned to bring Sinopharm Covid-19 vaccine for trial purposes.

2. Until 21 May 2021, the Sinopharm Covid-19 vaccine was not registered with NPRA yet.

3. There will be a big probability that the report by Kanger official is true. The company has started to register the said vaccine with NPRA.

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO).
--------------------
I want to stress on this.

If the Sinopharm was truly just registered with NPRA, the process of approval should be more shorter in time compared with the vaccine candidate which not been approved by WHO yet.

Note: Sinopharm vaccine has been approved by WHO,

On the Sputnik Covid-19 vaccine produced by Russia, Khairy said that Duopharma Biotech Bhd’s wholly-owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), which holds the distribution rights to the product, has three months to register the vaccine with the National Pharmaceutical Regulatory Agency (NPRA), after inking an agreement with the government earlier this month.

He said that the NPRA still requires further information on the vaccine.

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO). Sputnik has not received the EUL from WHO yet,” he said, referring to the Emergency Use Listing.

Source: https://www.malaymail.com/news/malaysia/2021/06/21/khairy-cansino-vaccine-to-arrive-in-malaysia-next-month-no-updates-yet-on-j/1983852

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO).
--------------------
I want to stress on this.

If the Sinopharm was truly just registered with NPRA, the process of approval should be more shorter in time compared with the vaccine candidate which not been approved by WHO yet.

Note: Sinopharm vaccine has been approved by WHO,

On the Sputnik Covid-19 vaccine produced by Russia, Khairy said that Duopharma Biotech Bhd’s wholly-owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), which holds the distribution rights to the product, has three months to register the vaccine with the National Pharmaceutical Regulatory Agency (NPRA), after inking an agreement with the government earlier this month.

He said that the NPRA still requires further information on the vaccine.

“However, NPRA also said that it would simplify the registration process if Sputnik gets emergency use (status) from the World Health Organisation (WHO). Sputnik has not received the EUL from WHO yet,” he said, referring to the Emergency Use Listing.

Source: https://www.malaymail.com/news/malaysia/2021/06/21/khairy-cansino-vaccine-to-arrive-in-malaysia-next-month-no-updates-yet-on-j/1983852

No report about it. The time schedule is lapsed.
But for me I stressed on their relation with Sinopharm and their ability to be an elected distributor for the vaccine in Malaysia.

By the way, the Sinophar vaccine has been finished their 3rd Trial, and already approved by WHO.

MrWinMoney PN19 in-coming? Saw it everywhere.
----------------------
PN-19? What is it, bro? Is it a tittle for a ghost movie?

An update on the prospect of Kanger to be involved as the distributor of Sinopharm Covid-19 vaccine in Malaysia:

Report 1: 9 March 2021.

Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.

In a bourse filing today, the group said the 10,000 doses of the vaccine will be for trial purposes and that it will be getting the necessary approvals from the relevant authorities.

“The first batch of vaccines is expected to arrive in May 2021,” Kanger stated.
Sinopharm has Covid-19 vaccine candidates that are undergoing stage 3 clinical trials

Source: https://www.theedgemarkets.com/article/kanger-receive-10000-doses-sinopharm-covid19-vaccine%C2%A0-may-trial-purposes

Report 2: 21 May2021.

The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA), says Khairy Jamaluddin (pic).

The National Covid-19 Immunisation Programme coordinating minister said that this DID NOT HAVE TO GO THROUGH PHARMANIAGA, the local registration product holder for the Sinovac vaccine.

He said there were several parties interested in bringing the Sinopharm vaccine from China.

“It can go through anybody else who wants to try and bring in the vaccine. It can be registered with the NPRA,” he said in a video late Thursday (May 20) to address several allegations made by Opposition leader Datuk Seri Anwar Ibrahim about the immunisation programme.
Source: https://mywinet.com/covid-19-those-who-want-to-bring-in-sinopharm-vaccine-can-register-it-with-npra-says-khairy/

Report 3: 27 May2021.
“the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.” Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/

MY FINDINGS:
1. Kanger planned to bring Sinopharm Covid-19 vaccine for trial purposes.

2. Until 21 May 2021, the Sinopharm Covid-19 vaccine was not registered with NPRA yet.

3. There will be a big probability that the report by Kanger official is true. The company has started to register the said vaccine with NPRA.

An update on the prospect of Kanger to be involved as the distributor of Sinopharm Covid-19 vaccine in Malaysia:

Report 1: 9 March 2021.

Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.

In a bourse filing today, the group said the 10,000 doses of the vaccine will be for trial purposes and that it will be getting the necessary approvals from the relevant authorities.

“The first batch of vaccines is expected to arrive in May 2021,” Kanger stated.
Sinopharm has Covid-19 vaccine candidates that are undergoing stage 3 clinical trials

Source: https://www.theedgemarkets.com/article/kanger-receive-10000-doses-sinopharm-covid19-vaccine%C2%A0-may-trial-purposes

Report 2: 21 May2021.

The government is open to any party that has the capability and clinical data of the Sinopharm Covid-19 vaccine to register it with the National Pharmaceutical Regulatory Agency (NPRA), says Khairy Jamaluddin (pic).

The National Covid-19 Immunisation Programme coordinating minister said that this DID NOT HAVE TO GO THROUGH PHARMANIAGA, the local registration product holder for the Sinovac vaccine.

He said there were several parties interested in bringing the Sinopharm vaccine from China.

“It can go through anybody else who wants to try and bring in the vaccine. It can be registered with the NPRA,” he said in a video late Thursday (May 20) to address several allegations made by Opposition leader Datuk Seri Anwar Ibrahim about the immunisation programme.
Source: https://mywinet.com/covid-19-those-who-want-to-bring-in-sinopharm-vaccine-can-register-it-with-npra-says-khairy/

Report 3: 27 May2021.
“the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.” Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/

MY FINDINGS:
1. Kanger planned to bring Sinopharm Covid-19 vaccine for trial purposes.

2. Until 21 May 2021, the Sinopharm Covid-19 vaccine was not registered with NPRA yet.

3. There will be a big probability that the report by Kanger official is true. The company has started to register the said vaccine with NPRA.

I want to give my views on whistlebower99's post about the RI.

Ingatkan cerdik punya naysayer. Rupanya sama seperti nama diberi. He He

@olangbolo.
--------------------
Dibawah inikan yang saya cakap. Bukan only comment after RI.

Saya berhenti setakat ini dahulu, sehimgga ada berita baru.
Teruskanlah cerita hantu awak tu. He He
18/06/2021 3:27 PM

olangbolo ada lagi plomoter bolo ni
---------------
Okaylah. Saya promoter bodoh. Minta awak pula lah cadangkan analisis awak.
Semua orang sedang tunggu analisis awak yang cerdik.
Sekadar nak cakap Kanger tipu,orang gi la belakang rumah saya pun boleh buat analisis.

Beri sebablah, apa yang tipu tu. Biar semua orang boleh kaji betul atau tidak.

JUST A THEORY TO SHARE

But as I looked at certain companies before, after the company approved the RI and setup the issue price for RI, the share price firstly will drop.

But near the date of the RI to be executed, the price will be markup higher than the issue price of the RI.

These scenario surely not be absolutely will happen to Kanger, but it has high chance or probability to follow suit.

AFTER ALL. TAYOR.

@zzzzzzz. Oleh sebab sejarahnya tak baiklah, company punya share pernah turun sampai harga terendah. Sekarang saja ia nampak ada naik balik walaupun sedikit, itu pun setelah company terlibat dengan Healthcare berkaitan dengan Covid-19.

Saya post balik Soal Jawab dengan BOD semasa AGM 2020 yang lalu.
Bukan nak ulang berita tetap boleh dijadikan panduan untuk kita sama-sama lihat balik arah tujuan BOD untuk FY2021.

---------
From QA at AGM 2020:
The company expected to turn profitable earliest in the FY2021.

1. The medical division will potentially contribute to the company growth in near future. A little explanation about the vaccine JV.
2. The Cyberjaya project has been terminated (should be Angkasa Project) caused the big loss in the last QRs (caused by write-off of the land held for property development).
3. The co also has a plan to use the land for medical center to coop with the medical business expansion.
4. Expected revenues from medical (RM10 mil) and construction (RM28 mil) for FY Ended 31 July 2021.
5. The big losses in 4th QR 2020 is from one-off items. Not to be incurred in the next QR reports.
6. The co is positively believes that the medical and construction will be able to contribute for a better net operating cash flow.
7. On the risk to be GN3 listing issuer. The risk is smaller because medical and construction businesses will help the co to increase the shareholders equity and eliminates the possibility of the co to be listed as GN3 listing co.

@zzzzzzz. Tak tahulah saya. Itu pandangan awak.
Yang saya yakin, masalah prestasi kewangan dari segi revenue dan kemungkinan mendapat untung adalah tinggi quarter dan FY21 ini. Saya rasa ianya akan direlease dari dikenakan GN3.
Sekadar ikhlas dari pandangan saya saja.

Cuma, sejarah company yang lalu adalah tak baik. Itu menyebabkan pelabur susah mahu percaya.

@TEEXIANX1840. Saya rasa masalah utama yang menyekat kenaikan harga saham sekarang ialah issue ICPS. Itu hari Ozura convert dan dump terus dalam pasaran. Pada masa itu harga Nexgram baru nak bergerak, tapi telah tersekat. Ramai bakal pelabur telah menyedari tentang perkara ini. Cuma harapannya ialah kalau BOD yang memiliki banyak ICPS untuk di convert tidak jual saham yang di convert. Itu mungkin akan memberi lebih keyakinan kepada bakal pelabur.
Ini kefahaman saya saja.

@zzzzzzz. Sabar saja. Dari awal pun Nexgram sudah jadi ikan masin.
Sudah simpan lama. Kalau mau simpan simpanlah. Kalau tidak cut loss saja.
Mau simpan ini ikan masin, semangat kena kuat.

Saya sendiri hari ini nak cakap lagi saya bukannya operator.
Sekadar seorang pelabur yang sudah lama tersekat sahamnya dalam Nexgram
Apa yang saya buat dari tahun dulu sampai sekarang sekadar nak defend pelaburan sendiri dalam Nexgram.

Setakat ini belum berjaya.
Tak tahulah usaha saya tak betul atau memang saham ikan masin Nexgram memang mempunyai banyak masalah dia.

Kalau nak bersabar, tetaplah bersabar.

Betul. Hanya cerita hantu 18KHarmoni saja yang betul. Jom semua kita dengar dan percaya.

Saya berhenti setakat ini dahulu, sehimgga ada berita baru.
Teruskanlah cerita hantu awak tu. He He

The price of Kanger's share is not subject to the attendance of me or other promoter in this forum. Also will not subjected to the naysayer's comments.
The price of any shares will depend on the market forces. The supply and demand for the specific share in the market will determine the share price.

I'm waiting for the progress of the proposed RI. Want to see what will happen to the price.
Up or down, let us see.

@18KHarmoni dan olangbolo.
Apahal ada personal masalah ke dengan saya? Promoter bodoh saja. He He

Atau rancangan SPEKULATIF AWAK Untuk burukkan Kanger dah terbongkar. Nak dapatkan harga rendah.

Kata Kanger scam mou, tapi asyik dok tunggu kaunter ni saja.
Apa hal benda mau cari.

Yang tambah tukar akaun bukan saya.
Yang cipta double atau triple akaun tu macam olongbolo barangkali.
Entah-entah twin atau triplet siapa lah tu. He He

olangbolo . Thanks olangbolo for your recognition.

@18KHarmoni. Terpulang kamulah. Penuh dengan andaian buruk saja kepada semua orang, semua pihak.........

@18KHarmoni. Kalau awak duduk kutuk saja Kanger, adakah awak rasa ia akan memberi kebaikan kepada pemegang saham sedia ada yang berada di tingkat atas?

Saya bukannya agen promoter berbayar, tetapi salah seorang pemegang saham Kanger yang tersekat beli Kanger pada harga 10.5 sen baru-baru ini.

@18KHarmoni.
Nasihat saya, harmoni harmoni kan diri awak tu dengan banyak perkara.

Ambil juga perkara positif untuk kebaikan diri dan orang lain.

Nexgram mana ada operator sekarang. Sabarlah

Noobie123 -----
Why bank don't want to lend? If company keep losing money, how to lend? Banks also don't want the shares. Banks all same. If you got money, they lend you money. If you no money, they all run away.
------------------
I agree with this idea. Thank you.

I have to cautiously trade/invest in many companies in BURSA as so many companies already did or proposed to do their own RI and PP.

A good reminder then.

18KHarmoni ....... the issue is kanger jual mou...
--------------
Atas issue inilah saya cuba cari maklumat dan cuba share maklumat berkenaan dengan MOU dan agreement yang telah dibuat oleh Kanger. Mungkin ada ketinggalan maklumat, tetapi hakikatnya saya nampak ada betul dan ada juga benda yang boleh dipersoalkan.

Artikel blog boleh dilihat dan dijadikan panduan kalau sesuai bagi individu. Bukan suatu paksaan untuk menerimanya pun.

https://klse.i3investor.com/blogs/mzm511/2021-06-07-story-h1566103030-The_Currents_Status_of_MOUs_and_Agreements_Relating_To_KANGER_0170.jsp

Noobie123 It is a collaborative agreement
--------------------
Yes. The specific scope of the agreement is a collaboration, not the JV.

@BilisMasin.

I don't know much about the construction industry.

As reported, VCSB (the JV partner of Kanger Ventures, a subsidiary of Kanger) was appointed as the main contractor for the said project.

VCSB was appointed as the main contractor for foundation and main building works of a project.
Kanger Ventures shall be responsible for the entire project management, financial and entire administration of the Project

05-Mar-2021 4,000,000 units @RM0.032
08-Mar-2021 8,000,000 units @RM0.032
16-Mar-2021 6,000,000 units @RM0.033
18-Mar-2021 90,000,000 units @RM0.033
03-June-2021 67,000,000 units @RM0.034
-----------------------
See these:

If they unload even @3.5 sen, they still have small profit to chewwww.

@olangbolo. Guy save yr money& love yr family..after this RI , Share consol 1:4 & 1:10
--------------------------
Tak semestinya buat consolidation. Consolidation bergantung kepada keperluan kewangan syarikat dan insider plan.

Semasa RI, semua akan subscribe, termasuk insider. Ada ke mereka akan buat conso kalau keadaan tidak memerlukan? Conso kemungkinan boleh merugikan semua pihak termasuk menurunkan harga saham yang dipegang oleh insider sendiri.
ATAU ADA MEREKA KISAH?



price till 28/6 will be hang 6-7 sen only!
--------------------
Kalau macam ni, baguslah. Saham kemungkinan tak turun lagi lebih rendah dari harga RI dia 6 sen.
Kalau betul tekaan Nujum Pak Belalang yang cerdik @olangbolo, nanti kempunanlah siapa yang nak tunggu beli @ 5.5 sen dalam jangka masa terdekat ini.

18KHarmoni Every QR is negative.
--------------------------------
Yes. For the last 4 QR reports. One of the main factor is the pandemic effect.
Before that, kanger was a profitable company.

It's simple. Just refer this to see the QR results:

https://klse.i3investor.com/servlets/stk/fin/0170.jsp

@18KHarmoni.

Next, its will be. After the proposal be approved in the incoming EGM on 28.6.2021

PROPOSED DIVERSIFICATION OF THE EXISTING PRINCIPAL ACTIVITIES OF KANGER AND ITS SUBSIDIARIES TO INCLUDE CONSTRUCTION AND RELATED ACTIVITIES

@olangbolo.
4) ploses ploses haiyaaa u manyakk bolo maximum laa
------------------------------------
Inikan sedang proses:

Report 1: The Sinopharm Covid-19 vaccine is in the process of being approved in Malaysia, including by the National Pharmaceutical Regulatory Agency (NPRA).

“We will ensure that we obtain the required approvals from relevant authorities before we commence distribution of the Sinopharm vaccines.

“Once approvals are obtained, the people of Sabah will be one of the early recipients of the Sinopharm vaccines,” Kuah said.

(Source: https://www.theedgemarkets.com/article/kanger-signs-mou-sabah-govt-procure-chinas-sinopharm-covid19-vaccines).

Report 2: Kanger International executive director Steven Kuah told reporters that, “the process of registering the Sinopharm vaccine (with NPRA) has started and we hope to receive some good news on its approval soon.”

(Source: https://www.freemalaysiatoday.com/category/nation/2021/05/27/sabah-signs-mou-with-private-firm-to-obtain-sinopharm-vaccine/ )

@olangbolo. Sangat sesuai dengan nama yang awak pilih tu. He He
--------------
Kanger is still progressing in its current business, which is bamboo flooring and related products, and Kanger also in its plan to venture in other business activities.

1. The company already involved in construction services.
2. In a process to acquire Properties business
3. In a process to acquire a company which involved in a construction material trading.
4. And of course a plan for Covid-19 vaccine business, they just in the process of trying to secure the said business. It's true to say that the most critical aspect to get is the approval of Sinopharm vaccine in Malaysia by government/NPRA.

8dragon MZM2511 is INED of NG...let him handles and oversee the operation of NG...hopefully NG can reach to 8 cents in near term...
-----------------

Tak kisahlah kata apa pun. "Agi idup agi ngelaban", Selagi boleh, selagi itu berjuang.

Lagi pun saya ada banyak masa sekarang.
Cuti atau bekerja dari rumah akibat pandemik Covid-19. He He

4. A Joint Venture Agreement (JVA) between IBSB, a wholly owned subsidiary of Nexgram with Faldze Holding Sdn Bhd (FHSB), relating to the sub-construction contract job awarded to Nexgram’s subsididary related to Central Spine Road Pakej 3: Gua Musang with contract sum of RM145 million.

Remarks:
1. This sub-construction contract awarded and has been signed.
2. The project had commenced on 16 July 2020 and should be in its progress as no report about the project delay has been reported by the company yet by to date.
3. There is no substantial contribution from the contract reported to the company revenue and earnings in the last quarterly report of the company, 2QR 2021.
4. This contract is not expected to have any material effect on the earnings per share, net assets per share, share capital and substantial shareholders’ shareholding of the Company for the financial year ending 31 July 2021.
5. However, it is expected that the JVA will contribute positively to the future revenue of the Group.

3. A Sale and Purchase Agreement between NMED Industries Sdn Bhd, a wholly owned subsidiary of Nexgram with AHSB, relating to the proposed acquisition of 61 percent shareholding in Arita Plastic Industries Sdn Bhd which involves in manufacturing of medical plastic products.

Remarks:
1. This Sale and Purchase Agreement has been finalized and completed.
2. There first contribution from Arita Plastic Industries, the newly acquired subsidiary which is involves in manufacturing of medical plastic product, has been reported in the last quarterly report of the company, 2QR 2021.
3. The Group’s revenue increased tremendously in 2QR 2021 by 73.2% mainly due to revenue contribution from the new division (i.e. healthcare) which included from manufacturing of medical plastic products.

2. Several agreements between Nexgram or its subsidiary and other parties, relating to the company’s healthcare online system / app namely TracVirus and SafeTravelPass services.

Remarks:
1. The agreements relating to the online system / app namely TracVirus and SafeTravelPass was being enforced and the systems /apps services is still ongoing. This service potentially will contribute more revenue for the company when the Malaysia’s borders open.
2. The contribution from the TracVirus services has been reported in the last quarterly report of the company, which is the 2QR 2021.
3. The Group’s revenue increased tremendously in 2QR 2021 by 73.2% mainly due to revenue contribution from the new division (i.e. healthcare) which included providing TracVirus Covid-19 related services.

1. Several agreements between Nexgram or its subsidiary and other parties, relating to the distribution of Covid-19 Diagnostic Test Kit.

Remarks:
1. The agreements relating to the distribution of Covid-19 Diagnostic Test Kit was being enforced and the Covid-19 test kit business is still ongoing.
2. The contribution of the Covid-19 test kit business has been reported in the last three quarterly report of the company, which are the 4QR 2020, 1Q2 2021 and 2QR 2021.
3. The Group’s revenue increased tremendously in 2QR 2021 by 73.2% mainly due to revenue contribution from the new division (i.e. healthcare) which included distribution of Covid-19 test kits.

No. 1, 2, dan 3

@TPC007. Bacalah betul-betul. ada yang jadi. ada yang belum pasti.
Tengok saja tak nak baca.
Kemudian dok meracau semua tak jadi.


Nak jadi agen pesaing Nexgram, kenalah rajin sikit. He He

They disposed because, they probably want to to manipulate the issuance price of the PP.
So they can subscribe the shares at a low price.
Just my assumption only.